Collagen Matrix Vs Mitomycin-C in Trabeculectomy and Combined Phacoemulsification and Trabeculectomy: a Randomized Controlled Trial

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2016 Dec 31

PMID 28034308

Citations 5

Authors

Angelo P Tanna

Alfred W Rademaker

C Gustavo De Moraes

David G Godfrey

Steven R Sarkisian Jr

Steven D Vold

Robert Ritch

Affiliations

Soon will be listed here.

Abstract

Background: Antifibrotic agents are commonly utilized to enhance the success rates of trabeculectomy. Novel approaches to further improve success rates and reduce the risks of complications are needed. The purpose of this study was to compare intraocular pressure (IOP)-lowering efficacy and safety of trabeculectomy or combined phacoemulsification and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matrix (CM).

Methods: A prospective, multicenter, randomized controlled trial was performed. Ninety-five eyes of 94 patients with uncontrolled glaucoma despite medical therapy, without previous incisional glaucoma surgery underwent trabeculectomy (85 eyes) or combined phacoemulsification and trabeculectomy (10 eyes) and were randomized to MMC or CM. One eye of each subject was analyzed. Patients were followed for 24 months. The criteria for complete success were IOP >5 and ≤21 mmHg with at least a 20% reduction below medicated baseline without additional glaucoma surgery or medications. The main outcome measures were complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.

Results: The baseline IOPs were 20.4 ± 6.0 mmHg and 21.2 ± 6.1 (mean ± standard deviation, p = 0.49) on 3.2 ± 1.1 and 3.1 ± 1.0 medications (p = 0.53) compared to 11.8 ± 5.2 and 12.8 ± 3.7 (p = 0.36) on 0.5 ± 0.8 and 0.6 ± 1.0 medications (p = 0.63) at 2 years in the MMC and CM groups, respectively. Kaplan-Meier analysis demonstrated complete success rates were similar in both groups at 24 months: 38.4 ± 7.6% with MMC and 56.2 ± 7.9% with CM (mean ± standard error, p = 0.112, log rank test); however, a significantly higher incidence of failure due to persistent hypotony was observed with MMC (p = 0.002).

Conclusions: Use of the CM implant at the time of trabeculectomy or combined phacoemulsification and trabeculectomy is associated with similar complete success rates compared to adjunctive MMC; however, the risk of persistent hypotony is higher with MMC.

Trial Registration: ClinicalTrials.gov registration number NCT01440751 . Registered 9/14/11.

Citing Articles

Clinical Impact of the Use of Ologen in Filtering Surgery Performed in Uncontrolled Glaucoma.

Navero-Rodriguez J, Boldu-Roig J, Pinilla L, Vidal-Marti M, Anton A J Clin Med. 2024; 13(15).

PMID: 39124730 PMC: 11312430. DOI: 10.3390/jcm13154463.

Commentary: Implantable collagen devices in optimizing filtering success - The holy grail?.

Krishnadas R Indian J Ophthalmol. 2021; 69(10):2739-2740.

PMID: 34571625 PMC: 8597440. DOI: 10.4103/ijo.IJO_1304_21.

Ethics of Glaucoma Widgets.

Dada T, Ramesh P, Sethi A, Bhartiya S J Curr Glaucoma Pract. 2021; 14(3):77-80.

PMID: 33867754 PMC: 8028034. DOI: 10.5005/jp-journals-10078-1288.

Evaluating glaucoma surgeries in the MIGS context.

Dhingra D, Bhartiya S Rom J Ophthalmol. 2020; 64(2):85-95.

PMID: 32685772 PMC: 7339697.

Phacoemulsification with or without goniosynechialysis for angle-closure glaucoma: a global Meta-analysis based on randomized controlled trials.

Wang N, Jia S Int J Ophthalmol. 2019; 12(5):826-833.

PMID: 31131244 PMC: 6520268. DOI: 10.18240/ijo.2019.05.20.

References

Chen H, Ritch R, Krupin T, Hsu W . Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci. 2006; 47(12):5310-4. DOI: 10.1167/iovs.06-0378. View

Derick R, Evans J, Baker N . Combined phacoemulsification and trabeculectomy versus trabeculectomy alone: a comparison study using mitomycin-C. Ophthalmic Surg Lasers. 1998; 29(9):707-13. View

Rosentreter A, Gaki S, Cursiefen C, Dietlein T . Trabeculectomy using mitomycin C versus an atelocollagen implant: clinical results of a randomized trial and histopathologic findings. Ophthalmologica. 2014; 231(3):133-40. DOI: 10.1159/000356400. View

Jampel H, Solus J, Tracey P, Gilbert D, Loyd T, Jefferys J . Outcomes and bleb-related complications of trabeculectomy. Ophthalmology. 2012; 119(4):712-22. DOI: 10.1016/j.ophtha.2011.09.049. View

Marey H, Mandour S, Ellakwa A . Subscleral trabeculectomy with mitomycin-C versus ologen for treatment of glaucoma. J Ocul Pharmacol Ther. 2012; 29(3):330-4. DOI: 10.1089/jop.2012.0120. View

Hung H, Wang S, ONeill R . A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biom J. 2006; 47(1):28-36. DOI: 10.1002/bimj.200410084. View

Law S, Hosseini H, Saidi E, Nassiri N, Neelakanta G, Giaconi J . Long-term outcomes of primary trabeculectomy in diabetic patients with primary open angle glaucoma. Br J Ophthalmol. 2013; 97(5):561-6. DOI: 10.1136/bjophthalmol-2012-302227. View

Johnson M, Sarkisian Jr S . Using a collagen matrix implant (Ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex-PRESS mini glaucoma device: a 12-month retrospective review. J Glaucoma. 2013; 23(9):649-52. DOI: 10.1097/IJG.0000000000000018. View

Dietlein T, Lappas A, Rosentreter A . Secondary subconjunctival implantation of a biodegradable collagen-glycosaminoglycan matrix to treat ocular hypotony following trabeculectomy with mitomycin C. Br J Ophthalmol. 2013; 97(8):985-8. DOI: 10.1136/bjophthalmol-2013-303357. View

10.

Boey P, Narayanaswamy A, Zheng C, Perera S, Htoon H, Tun T . Imaging of blebs after phacotrabeculectomy with Ologen collagen matrix implants. Br J Ophthalmol. 2010; 95(3):340-4. DOI: 10.1136/bjo.2009.177758. View

11.

He M, Wang W, Zhang X, Huang W . Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis. PLoS One. 2014; 9(1):e85782. PMC: 3896400. DOI: 10.1371/journal.pone.0085782. View

12.

Rosentreter A, Schild A, Jordan J, Krieglstein G, Dietlein T . A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma. Eye (Lond). 2010; 24(9):1449-57. DOI: 10.1038/eye.2010.106. View

13.

Senthil S, Rao H, Babu J, Mandal A, Garudadri C . Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma. Indian J Ophthalmol. 2013; 61(7):338-42. PMC: 3759104. DOI: 10.4103/0301-4738.109520. View

14.

Gedde S, Herndon L, Brandt J, Budenz D, Feuer W, Schiffman J . Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012; 153(5):804-814.e1. PMC: 3653167. DOI: 10.1016/j.ajo.2011.10.024. View

15.

Cillino S, Di Pace F, Cillino G, Casuccio A . Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond). 2011; 25(12):1598-606. PMC: 3234465. DOI: 10.1038/eye.2011.219. View

16.

Hsu W, Spilker M, Yannas I, Rubin P . Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000; 41(9):2404-11. View

17.

Narayanaswamy A, Perera S, Htoon H, Hoh S, Seah S, Wong T . Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Clin Exp Ophthalmol. 2013; 41(6):552-60. DOI: 10.1111/ceo.12058. View

18.

Solus J, Jampel H, Tracey P, Gilbert D, Loyd T, Jefferys J . Comparison of limbus-based and fornix-based trabeculectomy: success, bleb-related complications, and bleb morphology. Ophthalmology. 2012; 119(4):703-11. DOI: 10.1016/j.ophtha.2011.09.046. View

19.

Gedde S, Schiffman J, Feuer W, Herndon L, Brandt J, Budenz D . Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol. 2009; 148(5):670-84. DOI: 10.1016/j.ajo.2009.06.018. View

20.

Min J, Kee C, Sohn S, Lee H, Woo J, Yim J . Surgical outcome of mitomycin C-soaked collagen matrix implant in trabeculectomy. J Glaucoma. 2012; 22(6):456-62. DOI: 10.1097/IJG.0b013e31826ab6b1. View